Ampio Pharmaceutical (AMPE) 2.89 $AMPE
Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampio & Athersys - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 22, 12:21PM CDT
Amgen's (AMGN) first quarter 2015 results were impressive and the company raised its earnings outlook for the year.
BIIB: 423.57 (+1.46), ALNY: 118.00 (-2.70), GILD: 104.18 (-1.02), MDCO: 27.84 (+0.25), AMGN: 169.10 (+0.64), AMPE: 2.89 (+0.20), ABBV: 64.52 (+0.91), ATHX: 1.34 (+0.01)
Ampio Plunges as STRIDE Study on Ampion Fails - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 11:48AM CDT
Ampio Pharmaceuticals, Inc. (AMPE) announced disappointing results from the multiple injection STRIDE study AP008 on pipeline candidate Ampion.
VRX: 206.93 (-3.92), SHPG: 253.58 (+3.70), ARQL: 2.11 (-0.03), AMPE: 2.89 (+0.20)
Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET
PR Newswire - Tue Apr 21, 7:30AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced dial-in details for a scheduled investor call on Thursday, April 23, 4:30 p.m. ET. Participants are invited to dial in using the instructions as follows:
AMPE: 2.89 (+0.20)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 11:47AM CDT
SPPR: 2.55 (-0.16), FNRG: 3.11 (-0.86), BIOC: 3.15 (+0.02), NVGN: 7.40 (-0.30), AMPE: 2.89 (+0.20), TRIL: 20.67 (-2.53), CZR: 9.68 (-0.24), TLOG: 4.70 (-0.21), BCLI: 4.29 (-0.09), STDY: 10.10 (+0.11), GENE: 4.88 (-0.05), FARO: 44.64 (-0.93), ICON: 27.05 (+0.44), XXII: 1.50 (+0.04), XBIT: 27.55 (+0.18), UEC: 2.12 (+0.29), COOL: 1.40 (-0.21), CALA: 12.93 (-1.06), WPCS: 3.71 (-0.17), VIMC: 13.42 (+1.31)
Ampio Pharmaceuticals (AMPE) Stock Tanks Today after Treatment Fails To Reach Primary Endpoint
at The Street - Mon Apr 20, 9:45AM CDT
Ampio Pharmaceuticals (AMPE) shares have lost nearly two-thirds of their value after announcing weak results from its phase III study of pain reliever Ampion.
AMPE: 2.89 (+0.20)
Ampio Pharma off 58% premarket on failed trial results
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 8:32AM CDT
AMPE: 2.89 (+0.20)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 8:17AM CDT
GENE: 4.88 (-0.05), ROSG: 3.83 (-0.20), HAS: 71.73 (-1.82), RCL: 73.23 (-0.68), FNRG: 3.11 (-0.86), ADRO: 38.17 (-0.50), CNDO: 4.09 (-0.09), AMPE: 2.89 (+0.20), NVGN: 7.40 (-0.30), HQCL: 2.20 (-0.01)
AMPIO Announces Ampion(TM) STRIDE Study Results
PR Newswire - Mon Apr 20, 7:45AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the multiple injection STRIDE study AP008 did not reach its primary endpoint against the saline control even though there was a statistically significant reduction in pain compared to baseline for patients receiving Ampion(TM) (WOMAC A: p < 0.001). This pain reduction with Ampion(TM) was consistent across all sites and with our previously reported studies (SPRING and STRUT). Ampion(TM) is safe and well tolerated.
AMPE: 2.89 (+0.20)
Pharma Stocks Technical Review -- Novo Nordisk, Mallinckrodt, Theravance, Cempra, and Ampio Pharma
PR Newswire - Fri Mar 27, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MNK: 122.95 (-2.22), NVO: 56.37 (-0.17), AMPE: 2.89 (+0.20), CEMP: 38.71 (-0.15), THRX: 17.08 (+0.45)
Research and Markets: Ampio Pharmaceuticals's Optina (Macular Edema and Macular Degeneration) Drug Forecast and Market Analysis to 2023
Business Wire - Thu Mar 26, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qwdcbc/optina_macular) has announced the addition of the "Optina (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" report to their offering.
AMPE: 2.89 (+0.20)
Ampio Pharmaceuticals's Optina (Macular Edema and Macular Degeneration) Drug Forecast and Market Analysis to 2023
M2 - Thu Mar 26, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6qtnn/optina_macular) has announced the addition of the "Optina (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" report to their offering. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth. Optina is an orally-administered, ultra-low-dose capsule reformulation of the steroid danazol that is in Phase III of clinical development by Ampio Pharmaceuticals for the treatment of DME. An effective non-surgical drug treatment for DME is a high unmet need, and Optina is the only drug in late-phase development addressing this need. Scope - Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Optina including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Optina for the top country from 2013 to 2023. - Sales information covered for the US. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Macular Degeneration Overview 3.2 Macular Edema Overview 4 Disease Management 5 Competitive Assessment 6 Unmet Need and Opportunity 6.1 Overview 6.2 Treatment for Dry AMD 6.3 Longer-Acting Anti-VEGF Drug Therapy 6.4 Increased Efficacy of Anti-VEGF Therapy for wAMD 6.5 Less Invasive Drug Formulations 6.6 Awareness and Earlier Patient Diagnosis 6.7 Home Monitoring of AMD Progression 7 Pipeline Assessment 8 Optina 9 Appendix For more information visit http://www.researchandmarkets.com/research/n6...na_macular
AMPE: 2.89 (+0.20)
Shake Shack Shares Persist On The Hard To Borrow List
Interactive Brokers - Seeking Alpha - Tue Mar 24, 1:57AM CDT
Demand for shares of Shake Shack (NYSE: SHAK ) has been consistent during the past two weeks. Much of the demand was ignited roughly two weeks ago following the release of SHAK's fourth-quarter earnings, which the market initially had a hard time...
HLF: 46.63 (-0.13), TSLA: 219.44 (+10.03), SHAK: 62.00 (+2.00), MVIS: 3.62 (+0.26), AMRN: 2.34 (-0.05), CLF: 5.08 (+0.03), AXN: 1.77 (+0.01), NVGN: 7.40 (-0.30), AMPE: 2.89 (+0.20), FXCM: 2.13 (+0.02), RIG: 16.85 (-0.18), CNDO: 4.09 (-0.09), CEN: 16.93 (+0.07)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 4:37PM CDT
JRJC: 5.63 (+0.09), CLR: 51.80 (+0.98), ELY: 9.83 (-0.23), CCM: 6.96 (+0.15), DPLO: 34.52 (+0.26), AMPE: 2.89 (+0.20), UBS: 19.78 (-0.17), DNR: 8.21 (-0.26), GSAT: 3.14 (-0.06), CLNE: 7.16 (+0.03)
PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023
M2 - Mon Mar 23, 12:07PM CDT
Research and Markets (http://www.researchandmarkets.com/research/xb5dx3/pharmapoint) has announced the addition of the "PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023" report to their offering. Age-related Macular Degeneration Treatment Market Value to Exceed $10 Billion by 2023 This report provides annualized Macular Edema (ME) and Age-related Macular Degeneration (AMD) treatment market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023. Key topics covered include market characterization, unmet needs, research and development, and clinical trials assessment for the ME and AMD therapeutics markets. The Age-related Macular Degeneration treatment market across seven major countries (the US, UK, Germany, France, Spain, Italy and Japan) will almost double in value from $5.1 billion in 2013 to $10.1 billion by 2023, according to research and consulting firm The authors. The company's latest report* states that the main drivers for this considerable expansion, which will occur at a Compound Annual Growth Rate (CAGR) of 7.1%, are the new therapies entering the market and a global aging society, which will lead to increasing numbers of elderly people developing the age-related retinal disease. Catherine Daly, Ph.D., The authors's Analyst covering Neurology and Ophthalmology, says: The global AMD treatment market is overwhelmingly dominated by anti-vascular endothelial growth factor (anti-VEGF) drugs, including Lucentis, Avastin, and Eylea, which together accounted for 98% of sales for AMD in 2013. However, the anti-VEGF monopoly is set to take a dramatic tumble due to the launch of novel adjunctive therapies for wet AMD, Fovista and squalamine, and the introduction of two therapies for dry AMD, lampalizumab and emixustat, during the forecast period. These entrants will cause the anti-VEGFs' stronghold on the market to drop to 64% by 2023. The US accounted for 49% of the global AMD therapeutics market in 2013 and will achieve a 55% share by 2023, with its market value forecast to more than double from $2.5 billion to $5.6 billion over the same period. Daly comments: The new therapies entering the market will be the main drivers of growth in the US, with the wet AMD drugs Fovista, squalamine, and abicipar pegol launching in 2017, 2018, and 2020, respectively. Fovista is undergoing an extensive Phase III development program, and the data released to date have shown that this drug provides added benefit over the standard of care (anti-VEGF monotherapy). This indicates that the drug will enjoy good market success during the forecast period, with its US sales reaching $603 million by 2023. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology - Macular Edema 5 Epidemiology - Age-Related Macular Degeneration 6 Disease Management 7 Competitive Assessment 8 Unmet Need and Opportunity 9 Pipeline Assessment 10 Current and Future Players 11 Market Outlook 12 Appendix Companies Mentioned - Roche/Genentech - Novartis - Regeneron - Bayer - Valeant - Allergan - Alimera Sciences - Ampio Pharmaceuticals - Ophthotech - Acucela - Ohr Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/xb...harmapoint
AGN: 240.22 (+2.88), ALIM: 4.92 (-0.09), AMPE: 2.89 (+0.20), NVS: 103.45 (-0.62)
Strong On High Volume: Ampio Pharmaceuticals (AMPE)
at The Street - Wed Mar 18, 9:03AM CDT
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a strong on high relative volume candidate
AMPE: 2.89 (+0.20)
Market Maker Surveillance Report. AMPE, EBIX, ITG, AMRN, ECOM, LOCO, Winning Stocks With Lowest Price Friction For Friday, March 13th 2015
M2 - Mon Mar 16, 6:53AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 5298 companies with "abnormal" market making, 2008 companies with positive Friction Factors and 4028 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Friday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Ampio Pharmaceuticals Inc (NYSE:AMPE), Ebix Inc (NASDAQ:EBIX), INVESTMENT TECHNOLOGY GROUP (NYSE:ITG), Amarin Corp PLC (NASDAQ:AMRN), (NYSE:ECOM), (NASDAQ:LOCO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ITG: 31.57 (+0.29), ECOM: 10.52 (+0.09), AMRN: 2.34 (-0.05), LOCO: 28.22 (-0.34), EBIX: 29.77 (+0.86), AMPE: 2.89 (+0.20)
Regulators Want Drug Companies to Be Honest About FDA
at The Street - Wed Mar 04, 12:08PM CST
The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.
HEB: 0.25 (+0.01), AVEO: 2.04 (+0.12), AMPE: 2.89 (+0.20), SNY: 51.59 (+0.03)
Ampio Too Busy to Tell Investors Results of Eye Drug Study
at The Street - Wed Feb 25, 6:55AM CST
Ampio Pharmaceuticals completed a clinical trial of its diabetic macular edema drug Optina in November, but it is just too busy to disclose results.
AMPE: 2.89 (+0.20)
Technical Report on Pharma Stocks -- Novo Nordisk, Theravance, XenoPort, Cempra, and Ampio Pharma
PR Newswire - Wed Feb 18, 8:05AM CST
Editor Note: For more information about this release, please scroll to bottom.
NVO: 56.37 (-0.17), AMPE: 2.89 (+0.20), CEMP: 38.71 (-0.15), THRX: 17.08 (+0.45), XNPT: 7.42 (+0.12)
Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampio & Athersys - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 22, 12:21PM CDT
Amgen's (AMGN) first quarter 2015 results were impressive and the company raised its earnings outlook for the year.
BIIB: 423.57 (+1.46), ALNY: 118.00 (-2.70), GILD: 104.18 (-1.02), MDCO: 27.84 (+0.25), AMGN: 169.10 (+0.64), AMPE: 2.89 (+0.20), ABBV: 64.52 (+0.91), ATHX: 1.34 (+0.01)
Ampio Plunges as STRIDE Study on Ampion Fails - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 11:48AM CDT
Ampio Pharmaceuticals, Inc. (AMPE) announced disappointing results from the multiple injection STRIDE study AP008 on pipeline candidate Ampion.
VRX: 206.93 (-3.92), SHPG: 253.58 (+3.70), ARQL: 2.11 (-0.03), AMPE: 2.89 (+0.20)
Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET
PR Newswire - Tue Apr 21, 7:30AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced dial-in details for a scheduled investor call on Thursday, April 23, 4:30 p.m. ET. Participants are invited to dial in using the instructions as follows:
AMPE: 2.89 (+0.20)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 11:47AM CDT
SPPR: 2.55 (-0.16), FNRG: 3.11 (-0.86), BIOC: 3.15 (+0.02), NVGN: 7.40 (-0.30), AMPE: 2.89 (+0.20), TRIL: 20.67 (-2.53), CZR: 9.68 (-0.24), TLOG: 4.70 (-0.21), BCLI: 4.29 (-0.09), STDY: 10.10 (+0.11), GENE: 4.88 (-0.05), FARO: 44.64 (-0.93), ICON: 27.05 (+0.44), XXII: 1.50 (+0.04), XBIT: 27.55 (+0.18), UEC: 2.12 (+0.29), COOL: 1.40 (-0.21), CALA: 12.93 (-1.06), WPCS: 3.71 (-0.17), VIMC: 13.42 (+1.31)
Ampio Pharmaceuticals (AMPE) Stock Tanks Today after Treatment Fails To Reach Primary Endpoint
at The Street - Mon Apr 20, 9:45AM CDT
Ampio Pharmaceuticals (AMPE) shares have lost nearly two-thirds of their value after announcing weak results from its phase III study of pain reliever Ampion.
AMPE: 2.89 (+0.20)
Ampio Pharma off 58% premarket on failed trial results
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 8:32AM CDT
AMPE: 2.89 (+0.20)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 8:17AM CDT
GENE: 4.88 (-0.05), ROSG: 3.83 (-0.20), HAS: 71.73 (-1.82), RCL: 73.23 (-0.68), FNRG: 3.11 (-0.86), ADRO: 38.17 (-0.50), CNDO: 4.09 (-0.09), AMPE: 2.89 (+0.20), NVGN: 7.40 (-0.30), HQCL: 2.20 (-0.01)
AMPIO Announces Ampion(TM) STRIDE Study Results
PR Newswire - Mon Apr 20, 7:45AM CDT
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the multiple injection STRIDE study AP008 did not reach its primary endpoint against the saline control even though there was a statistically significant reduction in pain compared to baseline for patients receiving Ampion(TM) (WOMAC A: p < 0.001). This pain reduction with Ampion(TM) was consistent across all sites and with our previously reported studies (SPRING and STRUT). Ampion(TM) is safe and well tolerated.
AMPE: 2.89 (+0.20)
Pharma Stocks Technical Review -- Novo Nordisk, Mallinckrodt, Theravance, Cempra, and Ampio Pharma
PR Newswire - Fri Mar 27, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MNK: 122.95 (-2.22), NVO: 56.37 (-0.17), AMPE: 2.89 (+0.20), CEMP: 38.71 (-0.15), THRX: 17.08 (+0.45)
Research and Markets: Ampio Pharmaceuticals's Optina (Macular Edema and Macular Degeneration) Drug Forecast and Market Analysis to 2023
Business Wire - Thu Mar 26, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qwdcbc/optina_macular) has announced the addition of the "Optina (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" report to their offering.
AMPE: 2.89 (+0.20)
Ampio Pharmaceuticals's Optina (Macular Edema and Macular Degeneration) Drug Forecast and Market Analysis to 2023
M2 - Thu Mar 26, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n6qtnn/optina_macular) has announced the addition of the "Optina (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" report to their offering. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth. Optina is an orally-administered, ultra-low-dose capsule reformulation of the steroid danazol that is in Phase III of clinical development by Ampio Pharmaceuticals for the treatment of DME. An effective non-surgical drug treatment for DME is a high unmet need, and Optina is the only drug in late-phase development addressing this need. Scope - Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Optina including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Optina for the top country from 2013 to 2023. - Sales information covered for the US. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Macular Degeneration Overview 3.2 Macular Edema Overview 4 Disease Management 5 Competitive Assessment 6 Unmet Need and Opportunity 6.1 Overview 6.2 Treatment for Dry AMD 6.3 Longer-Acting Anti-VEGF Drug Therapy 6.4 Increased Efficacy of Anti-VEGF Therapy for wAMD 6.5 Less Invasive Drug Formulations 6.6 Awareness and Earlier Patient Diagnosis 6.7 Home Monitoring of AMD Progression 7 Pipeline Assessment 8 Optina 9 Appendix For more information visit http://www.researchandmarkets.com/research/n6...na_macular
AMPE: 2.89 (+0.20)
Shake Shack Shares Persist On The Hard To Borrow List
Interactive Brokers - Seeking Alpha - Tue Mar 24, 1:57AM CDT
Demand for shares of Shake Shack (NYSE: SHAK ) has been consistent during the past two weeks. Much of the demand was ignited roughly two weeks ago following the release of SHAK's fourth-quarter earnings, which the market initially had a hard time...
HLF: 46.63 (-0.13), TSLA: 219.44 (+10.03), SHAK: 62.00 (+2.00), MVIS: 3.62 (+0.26), AMRN: 2.34 (-0.05), CLF: 5.08 (+0.03), AXN: 1.77 (+0.01), NVGN: 7.40 (-0.30), AMPE: 2.89 (+0.20), FXCM: 2.13 (+0.02), RIG: 16.85 (-0.18), CNDO: 4.09 (-0.09), CEN: 16.93 (+0.07)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 4:37PM CDT
JRJC: 5.63 (+0.09), CLR: 51.80 (+0.98), ELY: 9.83 (-0.23), CCM: 6.96 (+0.15), DPLO: 34.52 (+0.26), AMPE: 2.89 (+0.20), UBS: 19.78 (-0.17), DNR: 8.21 (-0.26), GSAT: 3.14 (-0.06), CLNE: 7.16 (+0.03)
PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023
M2 - Mon Mar 23, 12:07PM CDT
Research and Markets (http://www.researchandmarkets.com/research/xb5dx3/pharmapoint) has announced the addition of the "PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023" report to their offering. Age-related Macular Degeneration Treatment Market Value to Exceed $10 Billion by 2023 This report provides annualized Macular Edema (ME) and Age-related Macular Degeneration (AMD) treatment market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023. Key topics covered include market characterization, unmet needs, research and development, and clinical trials assessment for the ME and AMD therapeutics markets. The Age-related Macular Degeneration treatment market across seven major countries (the US, UK, Germany, France, Spain, Italy and Japan) will almost double in value from $5.1 billion in 2013 to $10.1 billion by 2023, according to research and consulting firm The authors. The company's latest report* states that the main drivers for this considerable expansion, which will occur at a Compound Annual Growth Rate (CAGR) of 7.1%, are the new therapies entering the market and a global aging society, which will lead to increasing numbers of elderly people developing the age-related retinal disease. Catherine Daly, Ph.D., The authors's Analyst covering Neurology and Ophthalmology, says: The global AMD treatment market is overwhelmingly dominated by anti-vascular endothelial growth factor (anti-VEGF) drugs, including Lucentis, Avastin, and Eylea, which together accounted for 98% of sales for AMD in 2013. However, the anti-VEGF monopoly is set to take a dramatic tumble due to the launch of novel adjunctive therapies for wet AMD, Fovista and squalamine, and the introduction of two therapies for dry AMD, lampalizumab and emixustat, during the forecast period. These entrants will cause the anti-VEGFs' stronghold on the market to drop to 64% by 2023. The US accounted for 49% of the global AMD therapeutics market in 2013 and will achieve a 55% share by 2023, with its market value forecast to more than double from $2.5 billion to $5.6 billion over the same period. Daly comments: The new therapies entering the market will be the main drivers of growth in the US, with the wet AMD drugs Fovista, squalamine, and abicipar pegol launching in 2017, 2018, and 2020, respectively. Fovista is undergoing an extensive Phase III development program, and the data released to date have shown that this drug provides added benefit over the standard of care (anti-VEGF monotherapy). This indicates that the drug will enjoy good market success during the forecast period, with its US sales reaching $603 million by 2023. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology - Macular Edema 5 Epidemiology - Age-Related Macular Degeneration 6 Disease Management 7 Competitive Assessment 8 Unmet Need and Opportunity 9 Pipeline Assessment 10 Current and Future Players 11 Market Outlook 12 Appendix Companies Mentioned - Roche/Genentech - Novartis - Regeneron - Bayer - Valeant - Allergan - Alimera Sciences - Ampio Pharmaceuticals - Ophthotech - Acucela - Ohr Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/xb...harmapoint
AGN: 240.22 (+2.88), ALIM: 4.92 (-0.09), AMPE: 2.89 (+0.20), NVS: 103.45 (-0.62)
Strong On High Volume: Ampio Pharmaceuticals (AMPE)
at The Street - Wed Mar 18, 9:03AM CDT
Trade-Ideas LLC identified Ampio Pharmaceuticals (AMPE) as a strong on high relative volume candidate
AMPE: 2.89 (+0.20)
Market Maker Surveillance Report. AMPE, EBIX, ITG, AMRN, ECOM, LOCO, Winning Stocks With Lowest Price Friction For Friday, March 13th 2015
M2 - Mon Mar 16, 6:53AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 5298 companies with "abnormal" market making, 2008 companies with positive Friction Factors and 4028 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Friday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Ampio Pharmaceuticals Inc (NYSE:AMPE), Ebix Inc (NASDAQ:EBIX), INVESTMENT TECHNOLOGY GROUP (NYSE:ITG), Amarin Corp PLC (NASDAQ:AMRN), (NYSE:ECOM), (NASDAQ:LOCO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ITG: 31.57 (+0.29), ECOM: 10.52 (+0.09), AMRN: 2.34 (-0.05), LOCO: 28.22 (-0.34), EBIX: 29.77 (+0.86), AMPE: 2.89 (+0.20)
Regulators Want Drug Companies to Be Honest About FDA
at The Street - Wed Mar 04, 12:08PM CST
The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.
HEB: 0.25 (+0.01), AVEO: 2.04 (+0.12), AMPE: 2.89 (+0.20), SNY: 51.59 (+0.03)
Ampio Too Busy to Tell Investors Results of Eye Drug Study
at The Street - Wed Feb 25, 6:55AM CST
Ampio Pharmaceuticals completed a clinical trial of its diabetic macular edema drug Optina in November, but it is just too busy to disclose results.
AMPE: 2.89 (+0.20)
Technical Report on Pharma Stocks -- Novo Nordisk, Theravance, XenoPort, Cempra, and Ampio Pharma
PR Newswire - Wed Feb 18, 8:05AM CST
Editor Note: For more information about this release, please scroll to bottom.
NVO: 56.37 (-0.17), AMPE: 2.89 (+0.20), CEMP: 38.71 (-0.15), THRX: 17.08 (+0.45), XNPT: 7.42 (+0.12)
